March 1, 2024– JAL Therapeutics, a pioneering life sciences company focused on developing innovative treatments for Alzheimer’s disease and other chronic conditions, has joined the Academic Venture Exchange (AVX).
As a non-profit cooperative, AVX plays a crucial role in connecting groundbreaking, IP-backed ventures with the investment community, facilitating the growth and impact of scientific and technological advancements. By becoming a member of AVX, JAL Therapeutics aligns itself with a network of esteemed experts and leading research institutions across the United States.
This partnership underscores our commitment to pursuing breakthrough advancements in drug development and discovery, particularly our unique, patented small molecule platform aimed at the development of innovative drug candidates to modify the disease process of Alzheimer’s and other chronic diseases.
We are excited about the opportunities this membership presents for collaboration, innovation, and advancing our mission to explore new treatments for neurodegenerative and other CNS disorders.
For more information, please visit:
https://www.avx.io/ventures/jal-therapeutics
https://www.avx.io/about
